Valeant Pharmaceuticals, which has come under pressure for both its accounting and business practices, is the single largest holding in U.S. collateralized loan obligations, according to Deutsche Bank.

In a report published Wednesday, the bank said that U.S. CLOs have aggregate exposure of over $3 billion to Valeant loans, and this debt is very widely held across CLOs.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.